Definiens AG And MolecularMD Announce Partnership To Combine IHC Assays With Advanced Digital Pathology And Data Mining
Partnership Provides State-of-the-Art Patient Stratification Using Quantitative Tissue Assays For Clinical Development and Diagnostics
MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced a partnership agreement with MolecularMD to combine MolecularMD’s expertise in specialty diagnostic assays with Definiens’ quantitative tissue read-outs. MolecularMD is a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies.
“This agreement brings together MolecularMD’s proven track record in clinical assay development and companion diagnostics with Definiens’ unparalleled image analysis platform to provide the confidence of an integrated solution in stratifying patients.”
“Definiens’ technology already empowers smarter tissue-based diagnostics,” said Merrilyn Datta, chief commercial officer, Definiens. “This agreement brings together MolecularMD’s proven track record in clinical assay development and companion diagnostics with Definiens’ unparalleled image analysis platform to provide the confidence of an integrated solution in stratifying patients.”
The new partnership between the two diagnostics companies provides custom solutions that meet data and regulatory requirements for both biopharmaceutical clients and academic medical center oncology programs, including advanced solutions with assays, image analysis and data mining, combined with deep scientific, regulatory and pathology support.
“MolecularMD is uniquely suited to assist biopharmaceutical clients and academic medical centers with our clinical trial and regulatory expertise,” said Dan Snyder, president and chief executive officer, MolecularMD. “I’m thrilled that Definiens and MolecularMD have joined forces to provide these unique advantages, accelerating pipeline decisions and dramatically improving patient stratification from the pre-clinical phase.”
Definiens and MolecularMD will both attend the 2016 ASCO Annual Meeting, a conference that brings together over 30,000 worldwide oncology professionals. More information about the partnership can be found at Definiens Booth #15113 and MolecularMD Booth # 13111. ASCO 2016 will be held from June 3-7 at the McCormick Place in Chicago, Illinois. For more information about ASCO16, click here.
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents.
Jonathan Moll, +1 212-398-9680